About Ankyra
Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer. Systemic dosing of these powerful immune stimulants is severely limited by unintended activation of irrelevant bystander cells in circulation. We have developed methods to localize cytokines specifically and persistently within tumor tissue, creating intense hot spots of inflammation that awaken an anti-tumor immune response. We are translating this approach for the treatment of solid tumors.
Press Releases
Ankyra Therapeutics Announces Research Collaboration with the College of Veterinary Medicine at the University of Illinois at Urbana-Champaign
BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has entered into a formal research collaboration with the College of Veterinary Medicine at the University of Illinois Urbana-Champaign. Ankyra is developing a novel anchored...
Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute
BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has established a formal Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to pursue basic, translational and clinical research using Ankyra...
Ankyra Therapeutics Appoints Howard L. Kaufman, M.D. as President and Chief Executive Officer
Highly Accomplished Thought Leader with Proven Track Record of Immunotherapy Drug Development BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents, announced today that the Board...
Ankyra Therapeutics announces $45 Million Series B Financing and Appoints Howard L. Kaufman M.D. as Chief Medical Officer
BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the...